Literature DB >> 9580675

Extending the cleavage rules for the hammerhead ribozyme: mutating adenosine15.1 to inosine15.1 changes the cleavage site specificity from N16.2U16.1H17 to N16.2C16.1H17.

J Ludwig1, M Blaschke, B S Sproat.   

Abstract

In this paper, we show that an adenosine to inosine mutation at position 15.1 changes the substrate specificity of the hammerhead ribozyme from N16.2U16.1H17to N16.2C16.1H17(H represents A, C or U). This result extends the hammerhead cleavage triplet definition from N16.2U16.1H17to the more general N16.2Y16.1H17. Comparison of cleavage rates using I15.1ribozymes for NCH triplets and standard A15.1 ribozymes for NUH triplets under single turnover conditions shows similar or slightly enhanced levels of reactivity for the I15. 1-containing structures. The effect of I15.1 substitution was also tested in nuclease-resistant 2'- O -alkyl substituted derivatives (oligozymes), showing a similar level of activity for the NUH and NCH cleaving structures. The availability of NCH triplets that can be targeted without loss of efficiency increases the flexibility of ribozyme targeting strategies. This was demonstrated by an efficient cleavage of an HCV transcript at a previously inaccessible GCA site in codon 2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580675      PMCID: PMC147568          DOI: 10.1093/nar/26.10.2279

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  9 in total

1.  Reduction of target gene expression by a modified U1 snRNA.

Authors:  S A Beckley; P Liu; M L Stover; S I Gunderson; A C Lichtler; D W Rowe
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

2.  Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes.

Authors:  M Amarzguioui; G Brede; E Babaie; M Grotli; B Sproat; H Prydz
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

3.  Design, delivery and efficacy testing of therapeutic nucleic acidsused to inhibit hepatitis C virus gene expression in vitro and in vivo.

Authors:  Wolfgang H Caselmann; Matthias Serwe; Thomas Lehmann; Jnos Ludwig; Brian S Sproat; Joachim W Engels
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

Review 4.  Hammerhead redux: does the new structure fit the old biochemical data?

Authors:  Jennifer A Nelson; Olke C Uhlenbeck
Journal:  RNA       Date:  2008-02-20       Impact factor: 4.942

5.  Sequence specificity of the hammerhead ribozyme revisited; the NHH rule.

Authors:  A R Kore; N K Vaish; U Kutzke; F Eckstein
Journal:  Nucleic Acids Res       Date:  1998-09-15       Impact factor: 16.971

6.  Optimisation of the 10-23 DNAzyme-substrate pairing interactions enhanced RNA cleavage activity at purine-cytosine target sites.

Authors:  Murray J Cairns; Andrew King; Lun-Quan Sun
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

7.  Ribozyme cleavage of Plasmodium falciparum gyrase A gene transcript affects the parasite growth.

Authors:  Anwar Ahmed; Yagya D Sharma
Journal:  Parasitol Res       Date:  2008-06-05       Impact factor: 2.289

8.  A strategy for developing a hammerhead ribozyme for selective RNA cleavage depending on substitutional RNA editing.

Authors:  Masatora Fukuda; Kei Kurihara; Yasuyoshi Tanaka; Masanobu Deshimaru
Journal:  RNA       Date:  2012-07-13       Impact factor: 4.942

9.  Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA.

Authors:  Irena Vlatkovic; János Ludwig; Gábor Boros; Gábor Tamás Szabó; Julia Reichert; Maximilian Buff; Markus Baiersdörfer; Jonas Reinholz; Azita Josefine Mahiny; Uğur Şahin; Katalin Karikó
Journal:  Pharmaceutics       Date:  2022-01-29       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.